For decades, pancreatic cancer has been one of medicine’s most stubborn challenges—an aggressive disease often detected too late, resistant to most treatments, and with a five-year survival rate of just 3%. But this week, a new chapter in the fight against the disease opened with the publication of groundbreaking research in the New England Journal of Medicine. The study details the results of a Phase 1/2 clinical trial for daraxonrasib, a first-in-class drug that targets the RAS protein, a genetic driver in over 90% of pancreatic cancers. The findings suggest that for patients with previously treated, advanced RAS-mutated pancreatic cancer, daraxonrasib not only slows tumor progression but also doubles survival compared to standard chemotherapy alone.
The implications are seismic. Until now, RAS—long considered “undruggable”—has eluded targeted therapies despite its central role in cancer growth. Daraxonrasib, developed by Revolution Medicines, represents a breakthrough: a daily pill that acts as a “molecular glue,” binding to RAS and disrupting its ability to fuel tumor growth. The drug’s success in early trials has already prompted the U.S. Food and Drug Administration to fast-track its approval and allow expanded access for patients outside clinical settings.
According to the trial results, published May 7, 2026, patients receiving the highest dose of daraxonrasib (300 mg daily) experienced a median progression-free survival of 8.1 months—meaning their tumors did not worsen for more than eight months on average. Overall survival reached a median of 15.6 months, a dramatic improvement for a disease where most patients live less than a year after diagnosis. The study enrolled 168 patients with metastatic pancreatic cancer, all of whom had previously undergone chemotherapy, underscoring the drug’s potential as a second-line treatment option.
“This really feels like a watershed moment,” says Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute and lead investigator of the trial. “It’s going to shift how we think about treatment for pancreatic cancer overall.” Wolpin’s team, along with collaborators across the U.S., designed the trial to test both safety and efficacy. While side effects—including rash, mouth inflammation, nausea, and diarrhea—were common, most were manageable with supportive care, and the drug was deemed “much more tolerable than chemo” by Wolpin.
A Target Long Considered Impossible
RAS mutations have been a thorn in the side of cancer researchers for decades. The protein, which regulates cell growth, is overactive in nearly all pancreatic cancers, but its structure has made it nearly impossible to target with drugs. Until recently, RAS was considered “undruggable.” However, advances in chemistry have changed that landscape. Daraxonrasib is the first drug to successfully inhibit the “RAS-on” state, which is prevalent in pancreatic cancer, unlike other RAS inhibitors approved for lung and colorectal cancers that target different mutations.
The drug’s mechanism is innovative: rather than directly blocking RAS, it pairs with a protein called cyclophilin A inside cells, forming a complex that effectively “glues” RAS in a non-functional state. This approach has shown broad activity across the common RAS mutations found in pancreatic cancer, offering hope for a treatment relevant to nearly all patients with advanced disease.
What the Data Means for Patients
For patients like former Senator Ben Sasse, who was diagnosed with Stage 4 pancreatic cancer in 2025 and participated in a clinical trial of daraxonrasib, the drug has already made a tangible difference. Sasse described the drug’s side effects—particularly a severe rash—as challenging but noted that his tumors have shrunk significantly since beginning treatment. His experience, while anecdotal, reflects the broader promise of the drug for a disease that has long left patients with few options.
The Phase 1/2 trial results support the ongoing Phase 3 RASolute 302 trial, which is comparing daraxonrasib to standard second-line chemotherapy. Primary and final analysis of this pivotal trial will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on May 31, 2026. If the Phase 3 results confirm the earlier findings, daraxonrasib could soon become a standard treatment for advanced pancreatic cancer, offering patients a new lease on life.
Challenges and the Road Ahead
Despite the promising results, challenges remain. The most common side effects—rash, mouth sores, and gastrointestinal issues—can be significant, though manageable with supportive care. Not all patients respond equally to the drug, and researchers are still exploring why some benefit more than others.
Looking forward, the next critical checkpoint is the presentation of the Phase 3 trial results at ASCO on May 31. These findings will be closely scrutinized by regulators and could accelerate the drug’s path to approval. Revolution Medicines has already indicated its intention to submit a New Drug Application to the FDA based on the Phase 3 data, potentially bringing daraxonrasib to market within the next year.
Where to Find Updates and Resources
For patients, caregivers, and healthcare providers seeking the latest information, the following resources are available:
- Dana-Farber Cancer Institute’s announcement on the Phase 1/2 trial results
- Revolution Medicines’ official website for clinical trial updates
- National Cancer Institute’s pancreatic cancer information page
- ASCO Annual Meeting 2026 for Phase 3 trial results presentation
A New Era for Pancreatic Cancer Treatment
The publication of these results in the New England Journal of Medicine marks a turning point in the treatment of pancreatic cancer. For the first time, patients with advanced RAS-mutated pancreatic cancer have a targeted therapy that not only extends survival but also improves quality of life. While questions remain about long-term efficacy and optimal patient selection, the data is clear: daraxonrasib represents a major advance in oncology.
As the scientific community awaits the Phase 3 trial results, one thing is certain—What we have is not the end of the story, but the beginning of a new chapter in the fight against pancreatic cancer. For patients and their families, it offers a glimmer of hope that has been sorely needed for far too long.
We welcome your thoughts and experiences. Share your story or questions in the comments below, or share this article with someone who may benefit from this breakthrough.
